Feasibility of ultra-central stereotactic ablative irradiation in lung cancer undergoing nivolumab: a case report

Valerio Nardone¹, Maria Grazia Calvanese¹, Maria Mormile¹, Francesca Maria Giugliano¹, Pierpaolo Correale², Alfonso Reginelli³, Salvatore Cappabianca³, Cesare Guida¹

¹Unit of Radiation Oncology, Ospedale del Mare, Naples, Italy; ²Unit of Medical Oncology, Grand Metropolitan Hospital “Bianchi Melacrino Morelli”, Reggio Calabria, Italy; ³Department of Precision Medicine, University of Campania “L. Vanvitelli”, Naples, Italy

Correspondence to: Valerio Nardone, MD. Unit of Radiation Oncology, Ospedale del Mare, Naples, Italy. Email: v.nardone@hotmail.it.

Abstract: Oligometastatic disease represent a subgroup of cancer patients characterized by a low burden of metastatic disease potentially amenable for local treatments, aimed at achieving long-term remission. At the same time, in a percentage of the patient the localization of oligometastases can be challenging. In particular, ultracentral localization are characterized by the overlapping of the target volumes with critical structures such as proximal bronchial tree, trachea, esophagus, pulmonary vein or pulmonary artery. For this subset of localizations, the optimal dose and fractionation, as well as the safety of a radiotherapy approach, is still unknown. We report a case of an oligometastatic lung cancer patient undergoing therapy with Nivolumab that was successfully treated with thoracic stereotactic ablative radiation therapy (SABR) for a subcarinal lymph node metastasis. The patient began the radiation treatment concurrent with immunotherapy and reported no acute toxicity. The computed tomography (CT) scan 60 days after radiotherapy showed partial response and no acute toxicity. The subsequent positron emission tomography (PET)/CT scan performed 6 months after radiotherapy showed, conversely, a complete response of the irradiated lesion. The patient is still undergoing immunotherapy and show no signs of recurrence of disease. The association between immunotherapy and SABR seems to be useful in terms of outcomes, although at the present time we need more data on the safety of this combined approach in the subset of ultra-central localizations.

Keywords: Non-small cell lung cancer (NSCLC); stereotactic ablative radiation therapy (SABR); stereotactic radiation therapy; immunotherapy; case report

Received: 10 August 2020; Accepted: 30 October 2020; Published: 30 December 2020.
doi: 10.21037/pcm-20-40

View this article at: http://dx.doi.org/10.21037/pcm-20-40

Introduction

The role of radiotherapy in oligometastatic lung cancer patients has proven to be able to achieve long-term progression-free survival and its synergy with the novel molecules is a promising field of investigation (1).

Central localizations, defined as tumor located within 2 cm of the proximal bronchial tree, great vessels, trachea, heart, or other mediastinal structures, may be correlated to a higher incidence of severe adverse events (2). A subset of proximally central tumors called “ultra-central” tumors has recently been identified, and is characterized by the overlapping of the planned target volume (PTV) with the proximal bronchial tree, trachea, esophagus, pulmonary vein or pulmonary artery (3). For this subset of localizations, the optimal dose and fractionation, as well as the safety are still to be determined (4). At the same time, the synergy with chemotherapy or immunotherapy is still unknown.

Aim of this report is the description of a metastatic non-small cell lung cancer (NSCLC) patient undergoing nivolumab successfully treated with stereotactic radiation therapy in an ultracentral mediastinal metastasis.

We present the following case in accordance with the CARE reporting checklist (available at http://dx.doi.org/10.21037/pcm-20-40).
Case presentation

The reported patient was a 45-year-old male that was diagnosed in January 2018 with a locally advanced lung adenocarcinoma. The patient underwent upfront surgery (pT3N1) and adjuvant therapy (four cycles of chemotherapy with platinum 75 mg/m$^2$ and etoposide 100 mg/m$^2$, every 3 weeks).

The subsequent follow-up examinations were negative till October 2018, when a restaging computed tomography (CT) showed bone and node recurrence. The patient started immunotherapy with Nivolumab 40 mg/m$^2$ every 2 weeks, and achieved a complete response of disease.

Subsequent restaging was negative till April 2019, when a positron emission tomography (PET)/CT showed an adenopathy in the subcarinal area characterized by an increase in FDG consumption (SUVmax 5.5) (see Figure 1). The patient was still undergoing Nivolumab, 40 mg/m$^2$ every 2 weeks, and was referred to our Unit.

The patient underwent 4D simulation CT scan and we performed an elastic fusion between simulation CT and both diagnostic CT and PET/CT scans. The gross target volume (GTV) was delineated on diagnostic scans and transferred to simulation CT. The GTV was deformably propagated across phases to obtain internal target volume (ITV) using MIM Maestro software, a commercially deformable image registration tool (MIM Software Inc., Cleveland, OH, USA). The quality of contour propagation was inspected visually by a clinician with 25 years of experience in lung radiotherapy, and modifications were made where required. ITV was then expanded to 5 mm to obtain PTV. The radiation dose was chosen taking into consideration the dose constraints of the closer organs at risk (esophagus, trachea, aorta, heart).

The patient underwent stereotactic radiation therapy on the target lymph node, with 44 Gy in eight fractions (5.5 Gy/day, daily), prescribed at the isodose of 80% of the PTV (see Figure 1).

The treatment started during Nivolumab treatment, and subsequent immunotherapy cycle were not deferred.

The patient reported no acute or sub-acute toxicity, during the radiation treatment and in the following weeks. A CT scan performed 2 months after SABR showed no signs of toxicity and a partial response of the nodal recurrence.

The patient is still undergoing immunotherapy and last CT examination, in June 2020, show no signs of recurrence of disease.

Metastatic lung cancer has been synonymous with a lethal outcome and is generally considered incurable, although during the last decades there has been a slight improvement in overall survival (OS). Survival rates, however,
standardized for age shows very little variations among 67 countries (10–20%), and this may in part reflect generally unsuccessful therapeutic strategies (5).

It is of great interest to define subgroups of patients suffering from this heterogeneous disease that might benefit from different treatment strategies. One special subgroup comprises patients with limited tumour spread lying between localized cancers and disseminated metastatic cancer, termed oligometastatic disease. In particular, oligometastatic tumours are characterized by low volume metastatic disease with limited number and size of metastatic lesions (up to five and not necessarily in the same organ), potentially amenable for local treatment, aimed at achieving long-term remission (6).

At this regard, the role of radiation therapy especially for oligometastatic lung cancer patients, has shown to be able to achieve long-term progression-free survival, without significant treatment related toxicities, as in other pathologies (7). Its investigation with the novel molecules will be necessary in the next future for the optimal management of lung cancer patients, elderly included.

The association between immunotherapy and radiotherapy is currently under investigation in clinical trials, as it is considered a potential weapon in patients with metastatic NSCLC, especially in the oligometastatic setting.

Ultracentral localizations of NSCLC, at the same time, represent serious concerns regarding the balance of toxicities and outcomes (4,8), as this region was historically considered a “no fly zone” (9). Several studies have tried to develop different stereotactic approach for central tumors (10-12), although scarce data are available for ultra-central tumors (4). Other strategies that are under investigation include proton therapy or hadrontherapy (13).

Loi et al. showed that a biologically effective dose (BED) >75 Gy correlated with a significant gain in both progression-free survival and OS (4). Our patient underwent a BED of 68.2 Gy due to surrounding organs at risks. In literature median radiotherapy related grade >2 toxicities were 10% and treatment related mortality rate was 5% (14).

Systemic therapies are often correlated with poorer outcomes, as chemotherapy-naïve patients are frequently more radiosensitive in comparison to heavily-pretreated patients (15). Immunotherapy, at our knowledge, is still not investigated in the context of ultracentral radiotherapy.

In our case description we have shown a successful treatment of an oligometastatic NSCLC patient that underwent radiotherapy to ultracentral localization concomitant with immunotherapy treatment.

The strength of the reported case is the successful radiotherapy treatment of a critical localization, whereas the limitations are the impossibility of achieve a BED >100 Gy. The association between immunotherapy and radiation seems to be useful in terms of outcomes, although at the present time we need more data on the safety of this combined approach in the subset of ultra-central localizations.

Acknowledgments

Funding: None.

Footnote

Reporting Checklist: The authors have completed the CARE reporting checklist. Available at http://dx.doi.org/10.21037/pcm-20-40
Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at http://dx.doi.org/10.21037/pcm-20-40). The authors have no conflicts of interest to declare.

Ethical Statement: The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and national research committees and with the Helsinki Declaration (as revised in 2013). Written informed consent was obtained from the patient for publication of this manuscript and any accompanying images.

Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0/.

References
